Abstract:: PARPi have been explored and applied in the treatment of various cancers with remarkable efficacy, especially BRCA1/2 mutated ovarian, breast, prostate, and pancreatic cancers. However, PARPi renders inevitable drug resistance and showed high toxicity because of PARP-Trapping with long-term clinic tracking. To overcome the drug resistance and the high toxicity of PARPi, many novel methods have been developed including PROTACs. Being an event-driven technology, PROTACs needs a high affinity, low toxicity warhead with no steric hinderance in binding process. Veliparib shows the lowest PARP-Trapping effect but could hardly to be the warhead of PROTACs because of the strong steric hinderance. Other PARP1 inhibitors showed less steric hinderance but owns high PARP-Trapping effect. Thus, the development of novel warhead with high PARP1 affinity, low PARP1-Trapping, and no steric hinderance would be valuable. In this work, we reserved benzimidazole as the motif to reserve the low PARP1-Trapping effect and substituted the pyrrole by aromatic ring to avoiding the steric hindrance in PARP1 binding cave. Thus, a series of benzimidazole derivates were designed and synthesized, and some biological activities in vitro were evaluated including the inhibition for PARP1 enzyme and the PARP-Trapping effect using MDA-MB-436 cell line. Results showed that the compound 19A10 has higher PARP1 affinity( IC 50 = 4.62 nM)) and similar low PARP-Trapping effect compared with Veliparib( IC 50 (MDA-MB-436) >100 μM). Docking study showed that the compound 19A10 could avoiding the steric hindrance which was much better than Veliparib. So, the compound 19A10 could potentially be a perfect warhead for PARP1 degraders. Besides, because of the depletion of the PARP1 and the decreasing of the binding capability, we suppose that the PROTACs using 19A10 as the warhead would be no-PARP-Trapping effect. Furthermore, QSAR study showed that to develop novel compounds with high PARP1 binding affinity and low PARP-Trapping, we can choose the skeleton with substituent R 1 =H, R 2 =piperiazine, and R 3 with large tPSA. And, if we want to develop the compounds with high PARP1 binding affinity and high PARP-Trapping which can possibly improve the lethality against tumor cells, we can choose the skeleton with substituent R 1 =F, R 2 =3-methy-piperiazine, and R 3 with large tPSA.

A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer

Synthesis and biological evaluation of a tumor-selective degrader of PARP1

Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

Discovery of a potent and selective PARP1 degrader promoting cell cycle arrest via intercepting CDC25C-CDK1 axis for treating triple-negative breast cancer

Discovery of a potent PARP1 PROTAC as a chemosensitizer for the treatment of colorectal cancer

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer

KP372-1-Induced AKT Hyperactivation Blocks DNA Repair to Synergize With PARP Inhibitor Rucaparib via Inhibiting FOXO3a/GADD45α Pathway

An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer

Identification and evaluation of a novel PARP1 inhibitor for the treatment of triple-negative breast cancer

Combating Tumor PARP Inhibitor Resistance: Combination Treatments, Nanotechnology, and Other Potential Strategies

Synergistic Effect of Ubiquitin-Specific Protease 14 and Poly(ADP-Ribose) Glycohydrolase Co-Inhibition in BRCA1-Mutant, Poly(ADP-Ribose) Polymerase Inhibitor-Resistant Triple-Negative Breast Cancer Cells

Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy

Induction of Apoptosis in MDA-MB-231 Breast Cancer Cells by a PARP1-targeting PROTAC Small Molecule

BRCA1-mediated dual regulation of ferroptosis exposes a vulnerability to GPX4 and PARP co-inhibition in BRCA1-deficient cancers

Cascade Bioreactors Based on Host–Guest Molecular Inclusion Complexes for Triple‐Negative Breast Cancer Therapy via Inducing Ferroptosis

Identification of [1,2,4]Triazolo[4,3- a ]pyrazine PARP1 inhibitors with overcome acquired resistance activities

PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer

High Affinity and Low PARP-Trapping Benzimidazole Derivatives as a Potential Warhead for PARP1 Degraders

NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers

Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors